Carcinoma, Non-Small-Cell Lung Clinical Trials

805 clinical trials for Carcinoma, Non-Small-Cell Lung across international registries, including 72 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) — RECRUITING · PHASE3
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) — RECRUITING · PHASE3
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• A Study of DM005 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy — RECRUITING
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — RECRUITING · PHASE3
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting — RECRUITING
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC — RECRUITING · PHASE2
• KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) — RECRUITING · PHASE1
• KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) — RECRUITING
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC — RECRUITING · PHASE2
• Intratumoral N17350 in Advanced Solid Tumors — RECRUITING · PHASE1
• Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study — RECRUITING
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors — RECRUITING · PHASE1
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — RECRUITING · PHASE3
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers — RECRUITING · PHASE1
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — RECRUITING · PHASE3
• A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants — RECRUITING · PHASE1
• A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers — RECRUITING · PHASE1
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) — RECRUITING · PHASE2
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer — RECRUITING · PHASE1
• A Study of LY4175408 in Participants With Advanced Cancer — RECRUITING · PHASE1
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) — RECRUITING · PHASE2
• Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib — RECRUITING
• Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. — RECRUITING
• Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma — RECRUITING
• Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• MYLUNG Consortium Part 3: Observational Study — RECRUITING
• Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. — RECRUITING · PHASE3
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer — RECRUITING · PHASE1
• A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma — RECRUITING · PHASE2
• Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC — RECRUITING · PHASE2
• Confocal Laser Endomicroscopy VERification — RECRUITING · NA
• MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients — RECRUITING · NA
• A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors — RECRUITING · PHASE1
• Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC — RECRUITING · PHASE2
• Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer — RECRUITING · PHASE2
• Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy — RECRUITING · PHASE2
• IMPT Dose Escalation for NSCLC (HyDose) — RECRUITING · NA
• Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib — RECRUITING · PHASE1

Refine this search